ZMB Member Ken Herrmann
ZMB Member
Ken Herrmann
Next ZMB-Member
Prof. Dr. Ken Herrmann
University Hospital Essen
Hufelandstr. 55
45122 Essen
- +49 201 723 2073
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
- Development, application of new radiopharmaceuticals
- Diagnosis and therapy of thyroid carcinoma
- Diagnostics and therapy of endocrine tumors
- Diagnostics and therapy of prostate cancer
- Clinical use, optimization of PET, PET / CT
Selected Publications
-
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer : A multicentre retrospective studyIn: The Lancet Oncology Vol. 25 (2024) Nr. 9, pp. 1188 - 1201Online Full Text: dx.doi.org/ (Open Access)
-
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer : a consensus recommendation from the EORTC Imaging and Breast Cancer GroupsIn: The Lancet Oncology Vol. 24 (2023) Nr. 8, pp. e331 - e343Online Full Text: dx.doi.org/
-
Health-related quality of life and pain outcomes with [¹⁷⁷Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Vol. 24 (2023) Nr. 6, pp. 597 - 610Online Full Text: dx.doi.org/
-
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI) : A Single-Center Prospective Two-Arm StudyIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4194 - 4202Online Full Text: dx.doi.org/ (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia Vol. 36 (2022) Nr. 12, pp. 2845 - 2852Online Full Text: dx.doi.org/ (Open Access)
-
Radiotheranostics in oncology : current challenges and emerging opportunitiesIn: Nature Reviews Clinical Oncology Vol. 19 (2022) Nr. 8, pp. 534 - 550Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353Online Full Text: dx.doi.org/ (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: JAMA Oncology Vol. 7 (2021) Nr. 11, pp. 1635 - 1642Online Full Text: dx.doi.org/ (Open Access)
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology Vol. 22 (2021) Nr. 8, pp. 1115 - 1125Online Full Text: dx.doi.org/ (Open Access)
-
Nuclear medicine theranostics comes of ageIn: The Lancet Oncology Vol. 22 (2021) Nr. 11, pp. 1497 - 1498Online Full Text: dx.doi.org/
-
In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CTIn: Acta Biomaterialia Vol. 109 (2020) pp. 244 - 253Online Full Text: dx.doi.org/
-
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapyIn: The Lancet Oncology Vol. 21 (2020) Nr. 9, pp. e431 - e443Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Radiotheranostics : A roadmap for future developmentIn: The Lancet Oncology Vol. 21 (2020) Nr. 3, pp. e146 - e156Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer : A Prospective Single-Arm Clinical TrialIn: JAMA Oncology Vol. 5 (2019) Nr. 6, pp. 856 - 863Online Full Text: dx.doi.org/ (Open Access)
-
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 RadioembolizationIn: Liver Cancer Vol. 8 (2019) Nr. 6, pp. 491 - 504Online Full Text: dx.doi.org/ (Open Access)
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research Vol. 25 (2019) Nr. 24, pp. 7448 - 7454Online Full Text: dx.doi.org/ (Open Access)
-
The beginning of the end for conventional RECIST — novel therapies require novel imaging approachesIn: Nature Reviews Clinical Oncology Vol. 16 (2019) Nr. 7, pp. 442 - 458Online Full Text: dx.doi.org/
-
Consensus on molecular imaging and theranostics in prostate cancerIn: The Lancet Oncology Vol. 19 (2018) Nr. 12, pp. e696 - e708Online Full Text: dx.doi.org/
-
Extrahepatic Comorbidities Do Not Alter the Safety and Efficacy of Radioembolization of NAFLD-Associated HCCIn: Hepatology Vol. 68 (2018) Nr. Suppl. 1, pp. 852A - 853A
-
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer : a consensus recommendation from the EORTC Imaging GroupIn: The Lancet Oncology Vol. 19 (2018) Nr. 10, pp. e534 - e545Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signalingIn: Leukemia Vol. 27 (2013) Nr. 12, pp. 2301 - 2310Online Full Text: dx.doi.org/